Shin Miyakawa

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 3 EPO patents. Top assignees: Ribomic Inc., Cellmid Limited, Fujimoto Pharmaceutical Corporation. Active years: 2011-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shin Miyakawa. Retrieved from https://idiyas.com/inventor/shin-miyakawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 42.9

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 4.7

ph-index = 3

Forward Citations = 28(Granted Patents)

Company Filing History:

Fujimoto Pharmaceutical Corporation

patents

4. 1 out of 54

Ntt Communications Corporation

patents

5. 1 out of 846

Otsuka Pharmaceutical Company, Limited

patents

where one patent can have more than one assignee

Years Active: 2011-2019

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10260070 - Aptamer for NGF and use thereof (2019-04-16),

2. 9506070 - Aptamer against midkine and applications thereof (2016-11-29),

3. 8716230 - Methods for treatment or prevention of diseases associated with functional disorder of regulatory T cells (2014-05-06),

4. 8637656 - Nucleic acid capable of binding to immunoglobulin G and use thereof (2014-01-28),

5. 8515066 - Method, apparatus and program for establishing encrypted communication channel between apparatuses (2013-08-20),

6. 8128934 - Method for treatment or prevention of disease associated with functional disorder of regulatory T cell (2012-03-06),

7. 8080649 - Aptamer against midkine and use thereof (2011-12-20),

Title: Innovations of Shin Miyakawa

Introduction

Shin Miyakawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the development of aptamers. With a total of 7 patents to his name, his work has the potential to impact various medical applications.

Latest Patents

Miyakawa's latest patents include groundbreaking inventions such as an aptamer for nerve growth factor (NGF) and an aptamer against midkine. The first patent provides an aptamer that exhibits inhibitory activity against NGF, along with a complex that includes this aptamer and functional substances like drugs and diagnostic agents. The second patent focuses on an aptamer that binds to midkine, capable of forming a specific secondary structure, which is crucial for its functionality.

Career Highlights

Throughout his career, Shin Miyakawa has worked with notable companies, including Ribomic Inc. and NTT Communications Corporation. His experience in these organizations has allowed him to refine his skills and contribute to innovative projects in the biotechnology sector.

Collaborations

Miyakawa has collaborated with esteemed colleagues such as Yoshikazu Nakamura and Masatoshi Fujiwara. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and advancements in their respective fields.

Conclusion

Shin Miyakawa's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for advancements in medical applications, showcasing the importance of innovation in improving healthcare solutions.

Profile summary based on public USPTO records.